menu
    • menu
    [{"orgOrder":0,"company":"Immorna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"JCXH-105","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immorna \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ Not Applicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JCXH-211","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immorna \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immorna \/ Not Applicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"JCXH-108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immorna \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Immorna \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Immorna

    Menu

    Immorna

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immorna

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Immorna

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JCXH-108

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Immorna Secures Gates Foundation Grant for RSV Vaccine Development

                            Details : The funding aims to advance the clinical development of JCXH-108, which is a monovalent RSV vaccine being developed by Immorna using its proprietary mRNA and RTU-LNP technologies.

                            Brand Name : JCXH-108

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 26, 2024

                            Lead Product(s) : JCXH-108

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immorna

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Immorna

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JCXH-211,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immorna Receives FDA IND Clearance For JCXH-211 Study in Advanced Solid Tumors

                            Details : JCXH-211 is a first-in-class lipid nanoparticle (LNP) encapsulated srRNA, encoding the engineered human IL-12 protein. t is being investigated in advanced solid tumors.

                            Brand Name : JCXH-211

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 08, 2024

                            Lead Product(s) : JCXH-211,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immorna

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Immorna

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JCXH-105

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles V...

                            Details : JCXH-105, in preclinical trials has shown elicited robust and durable antigen-specific T cell responses and increase of antibody titers in rodents as well as in non-human primates.

                            Brand Name : JCXH-105

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : JCXH-105

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth